Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 302

1.

Risk factors for axillary lymph node metastases in clinical stage T1-2N0M0 breast cancer patients.

Zhang Y, Li J, Fan Y, Li X, Qiu J, Zhu M, Li H.

Medicine (Baltimore). 2019 Oct;98(40):e17481. doi: 10.1097/MD.0000000000017481.

2.

Patient delay and associated factors among Chinese women with breast cancer: A cross-sectional study.

Zhang H, Wang G, Zhang J, Lu Y, Jiang X.

Medicine (Baltimore). 2019 Oct;98(40):e17454. doi: 10.1097/MD.0000000000017454.

3.
4.

Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence after curative surgery.

Lee YS, Lee HS, Chang SW, Lee CU, Kim JS, Jung YK, Kim JH, Seo YS, Yim HJ, Lee CH, Woo SU, Seo JH, Yeon JE, Um SH, Byun KS.

Medicine (Baltimore). 2019 Sep;98(39):e17277. doi: 10.1097/MD.0000000000017277.

5.

Clinical efficacy of weekly cisplatin for treatment of patients with breast cancer.

Ma Y, Zhang NP, An N, Li WY, Zhao W, Liu YC.

Medicine (Baltimore). 2019 Sep;98(37):e17114. doi: 10.1097/MD.0000000000017114.

6.

Breast lesion size assessment in mastectomy specimens: Correlation of cone-beam breast-CT, digital breast tomosynthesis and full-field digital mammography with histopathology.

Wienbeck S, Uhlig J, Fischer U, Hellriegel M, von Fintel E, Kulenkampff D, Surov A, Lotz J, Perske C.

Medicine (Baltimore). 2019 Sep;98(37):e17082. doi: 10.1097/MD.0000000000017082.

7.

HER2 and Breast Cancer - A Phenomenal Success Story.

Hayes DF.

N Engl J Med. 2019 Sep 26;381(13):1284-1286. doi: 10.1056/NEJMcibr1909386. Epub 2019 Sep 10. No abstract available.

PMID:
31502769
8.

Essential oil extracted from erythrina corallodendron L. leaves inhibits the proliferation, migration, and invasion of breast cancer cells.

Xing X, Ma JH, Fu Y, Zhao H, Ye XX, Han Z, Jia FJ, Li X.

Medicine (Baltimore). 2019 Sep;98(36):e17009. doi: 10.1097/MD.0000000000017009.

9.

Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab.

Wang X, Cai L, Ye F, Li M, Ma L, Geng C, Song Z, Liu Y.

Medicine (Baltimore). 2019 Sep;98(36):e16937. doi: 10.1097/MD.0000000000016937.

10.

Effect of age at first use of oral contraceptives on breast cancer risk: An updated meta-analysis.

Ji LW, Jing CX, Zhuang SL, Pan WC, Hu XP.

Medicine (Baltimore). 2019 Sep;98(36):e15719. doi: 10.1097/MD.0000000000015719.

11.

Medications to Reduce Breast Cancer Risk.

Jin J.

JAMA. 2019 Sep 3;322(9):900. doi: 10.1001/jama.2019.12858. No abstract available.

PMID:
31479139
12.

Effects of infrared laser moxibustion on cancer-related fatigue in breast cancer survivors: Study protocol for a randomized controlled trial.

Mao H, Mao JJ, Chen J, Li Q, Chen X, Shen X, Zhao L, Wei J, Shen X.

Medicine (Baltimore). 2019 Aug;98(34):e16882. doi: 10.1097/MD.0000000000016882.

13.

Primary tumor resection for initially staged IV breast cancer: An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival.

Erol T, İmamoğlu NE, Aydin B, Taşkiran ZE, Esendağli G, Kösemehmetoğlu K, Baykal A.

Medicine (Baltimore). 2019 Aug;98(33):e16773. doi: 10.1097/MD.0000000000016773.

14.

High-intensity interval training can modulate the systemic inflammation and HSP70 in the breast cancer: a randomized control trial.

Alizadeh AM, Isanejad A, Sadighi S, Mardani M, Kalaghchi B, Hassan ZM.

J Cancer Res Clin Oncol. 2019 Oct;145(10):2583-2593. doi: 10.1007/s00432-019-02996-y. Epub 2019 Aug 10.

PMID:
31401675
15.

Lack of expression of ALK and CD30 in breast carcinoma by immunohistochemistry irrespective of tumor characteristics.

Nassif S, El-Zaatari ZM, Attieh M, Hijazi M, Fakhreddin N, Aridi T, Boulos F.

Medicine (Baltimore). 2019 Aug;98(32):e16702. doi: 10.1097/MD.0000000000016702.

16.

Risk Analysis for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving FEC100 Treatment.

Hayashi M, Nakazawa K, Hasegawa Y, Horiguchi J, Miura D, Ishikawa T, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Tanino H, Yamada K, Narui K, Kimura K, Akazawa K, Kohno N; JONIE STUDY GROUP.

Anticancer Res. 2019 Aug;39(8):4305-4314. doi: 10.21873/anticanres.13596.

PMID:
31366522
17.

Taxane-based chemotherapy and risk of breast cancer-related lymphedema: Protocol for a systematic review and meta-analysis.

Zhang Z, Zhang X, Chen S, Jiang J, Qi R, Zhang X, Xi Y, Li M, Zheng H, Hua B.

Medicine (Baltimore). 2019 Jul;98(30):e16563. doi: 10.1097/MD.0000000000016563.

18.

Diagnostic value of MRI combined with ultrasound for lymph node metastasis in breast cancer: Protocol for a meta-analysis.

Cai D, Lin T, Jiang K, Sun Z.

Medicine (Baltimore). 2019 Jul;98(30):e16528. doi: 10.1097/MD.0000000000016528.

19.

BNP as a potential biomarker for cardiac damage of breast cancer after radiotherapy: a meta-analysis.

Zhang C, Shi D, Yang P.

Medicine (Baltimore). 2019 Jul;98(29):e16507. doi: 10.1097/MD.0000000000016507.

20.

Use of preoperative mammography, ultrasonography, and MRI to predict nipple areolar complex involvement in breast cancer.

Lim S, Park G, Choi HJ, Kwon WJ, Kang BS, Bang M.

Br J Radiol. 2019 Oct;92(1102):20190074. doi: 10.1259/bjr.20190074. Epub 2019 Aug 13.

PMID:
31317763

Supplemental Content

Loading ...
Support Center